Thetis Awarded Key Patent on HEALER Technology

SOUTHPORT, CT–(Marketwired – Jan 27, 2016) – Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company focused on gastrointestinal and cardiometabolic diseases, announced today that the USPTO has granted patent US 9,242,008 providing composition of matter protection for our lead development candidates, TP-252 for familial adenomatous polyposis. The allowed claims include pharmaceutical compositions that are mineral amino-acid […]

Thetis Expands HEALER Technology Patent Estate

SOUTHPORT, Connecticut, June 20, 2014—Thetis Pharmaceuticals LLC (“Thetis”), an emerging biopharmaceutical company focused on cardio-metabolic diseases, announced today the filing of two patent applications that broaden its foundation for identification and selection of multiple new therapeutic compounds for development. The patents expand the company’s HEALER℠ Technology (High Efficiency Amino Lipid Enabled Release) with proprietary amino-lipid […]

Thetis Announces Closing of $5.7 Million Series A Financing

SOUTHPORT, Connecticut, May 3, 2013 – Thetis Pharmaceuticals LLC, a development stage pharmaceutical company focused on cardio-metabolic disease, announced today it has closed a $5.7 million Series A financing, led by Connecticut Innovations (CI), the state’s quasi-public authority responsible for technology investing in new technology innovation, and involving Stonehenge Partners and angel investors. The capital […]

Thetis Adds Todd Zion and Dennis Willson as Board Advisors

SOUTHPORT, Connecticut, January 3, 2012 — Thetis Pharmaceuticals LLC (“Thetis”), a development stage pharmaceutical company focused on cardio-metabolic disease, announced today the addition of Todd C. Zion, PhD, to its Scientific Advisory Board, and Dennis F. Willson to its Board of Managers. Todd Zion was founder, President and CEO of SmartCells, Inc., a biotechnology company […]

Thetis Secures $1.75 Million Seed Investment

SOUTHPORT, Connecticut, August 22, 2011 – Thetis Pharmaceuticals LLC, a development stage pharmaceutical company focused on cardio-metabolic disease, announced today that Connecticut Innovations (CI), the state’s quasi-public authority responsible for technology investing in new technology innovation, has made a $500,000 investment in Thetis as part of a $1.75 million funding round also involving Stonehenge Partners […]